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 Anterior cruciate ligament (ACL) ruptures are common injuries, specifically for young 
athletes, and in order to repair this injury, the patients must undergo ACL reconstructive surgery. 
This surgery commissions the use of autografts and allografts in order rebuild the torn ligament. 
Traditional autografts are the patellar tendon autograft, which is the most common, and the 
hamstring autograft. These grafts are made by transplanting tissue from the patellar tendon or the 
hamstring to the ruptured ACL. Allografts are another type of graft that involves transplanting 
tissue from a donor cadaver to the patient. Traditional autografts and allografts have been used 
for years even though they have nagging side effects such as donor site morbidity, loss of muscle 
strength, disease transmission, and graft rejection. However, now orthopedic doctors are looking 
into tissue-engineered grafts in order to circumvent these problems. 
 Tissue-engineered grafts are made of synthetic material, such as collagen, and stem cells. 
Theoretically, these grafts would not have the same problems that traditional autografts and 
allografts have, but research has shown that tissue-engineered grafts have their own drawbacks 
as well. The most glaring problem with tissue-engineered grafts is that they are not very durable, 
so graft failure is a common side effect. Orthopedic doctors are working on ways to improve the 
strength of tissue-engineered grafts, but these improvements have not been successfully tested on 
humans yet. Therefore, as of today, tissue-engineered grafts are not recommended as a successful 
alternative to traditional autografts and allografts. 
  





Anterior cruciate ligament (ACL) ruptures are a common injury in many young athletes, 
and this type of injury causes players to miss an entire season of play. This injury and recovery 
period is detrimental to players and their teams, so orthopedic doctors are actively searching for a 
way to shorten recovery time, prevent reinjury, and find a better surgery method with fewer side 
effects (Gobbi et al. 2006). The traditional method for treating ACL ruptures is to undergo ACL 
reconstructive surgery using traditional autografts and allografts. Autograft transplants involve 
transplanting tissue from one part of the patient’s body to the torn ACL. Usually, the tissue is 
taken from the patellar tendon in the knee or from the hamstring, and both of these autografts 
have proven to be effective in helping athletes recover from an ACL injury (Dhammi et al. 
2015). Allograft transplants involve moving tissue from a donor cadaver to the patient’s torn 
ACL, and this technique also helps athletes recover and return to play (Chang et al. 2003). 
Traditional autografts and allografts have been used for years as treatment for ACL 
injuries even though they have some major flaws, such as donor site morbidity or disease 
transmission. However, new ACL grafts using ligament tissue engineering are being developed. 
This new technique for creating grafts can possibly allow athletes to recover faster from ACL 
injuries, and these grafts may also be able to lower the incidence of reinjury in patients 
(Rathbone et al. 2012). This review will study literature detailing the advantages and drawbacks 
of traditional autografts and allografts, and it will also review literature describing the advantages 
and limitations of the new grafts being developed. Comparing the traditional autografts and 
allografts to the newer tissue-engineered grafts will examine if the newer grafts will overall be 
better than the traditional. 
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Traditional Autografts and Allografts 
 When treating an ACL injury, orthopedic doctors usually recommend ACL reconstructive 
surgery in order to stabilize the knee. This surgery involves replacing the torn ACL with another 
ligament using either a patellar tendon autograft, a hamstring autograft, or an allograft from a 
donor cadaver (Rathbone et al, 2012). These are the most popular grafts used, but they each have 
their own side effects that make recovery difficult for patients. 
Patellar Tendon Autograft (BPTB Graft) 
 The most recommended autograft is the patellar tendon autograft, and it is commonly 
considered the “gold standard” of grafts (Dhammi et al. 2015). The patellar tendon autograft, or 
the bone-patellar tendon-bone (BPTB) graft, is frequently chosen because when it has been 
clinically tested, it has usually had great results. The article by Dhammi et al. (2015) showed that 
83% of long-term patients receiving the BPTB graft now have normal knee function, and only 
1.6% of patients needed additional surgery due to failure of the BPTB graft. 83% satisfaction is a 
great statistic for many orthopedic doctors, but BPTB grafts also have their limitations. 
 Dhammi et al. (2015) also mentioned the disadvantages of the BPTB graft. Some common 
side effects of this graft are patellar tendon ruptures, patellar/tibial fractures, quadricep weakness, 
chronic anterior knee pain, difficulty kneeling, and numbness due to nerve damage during surgery. 
Also, in the study by Gobbi & Francisco (2015), the authors found that after performing isokinetic 
tests, which is a common test to determine strength of the muscles around the knee, the patients 
receiving a BPTB graft had significantly decreased quadricep strength 3 months after surgery 
compared to the other group of patients who received the hamstring autograft. This significant loss 
of quadricep strength was also observed in by Hiemstra, Webber, Macdonald, & Kriellaars (2000). 
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They found that subjects with the BPTB graft had decreased knee extension strength that was not 
seen in the study group receiving the hamstring graft. Loss of knee strength is one of the main 
reasons why it takes so long for athletes to recover from ACL injuries because they must take time 
to rebuild their muscle strength. The BPTB graft seems to exacerbate this problem. 
Hamstring Autografts 
 Although the bone-patellar tendon-bone graft is very popular, the hamstring autograft is 
becoming a highly recommended alternative. The hamstring autograft usually involves 
transplanting the semitendinosus tendon from the hamstring of the patient to replace the torn ACL, 
or surgeons can also remove the gracilis tendon with the semitendinosus tendon, which is also 
located in the hamstring (Dhammi et al. 2015). The main advantage the hamstring autograft has 
over the BPTB graft is that chronic knee pain is greatly reduced after surgery. Hamstring autografts 
also have a lower risk of failure compared to the common BPTB graft, and the quadricep muscle 
is much stronger when the hamstring autograft is harvested (Hiemstra et al. 2000). However, the 
hamstring autograft also has its drawbacks. 
 Dhammi et al. (2015) showed that some of the major disadvantages of the hamstring 
autograft are greatly reduced knee flexion strength, sciatic nerve palsy, and inferior fixation 
strength. Also, Clatworthy, Bulow & Bartlett (1999) found that there was significant tunnel 
widening in patients receiving the semitendinosus and gracilis grafts, which was not found in 
patients receiving the BPTB graft. Tunnel widening prevents the tendon from healing properly to 
the bone, and it is also associated with anterior knee laxity. It has also been implicated as a major 
cause for graft failure, which can lead to revision surgery to fix the failed hamstring graft (Srinivas, 
Kanthila, Saya, & Vidyasagar, 2016). Hamstring autografts also result in decreased hamstring 
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strength when compared to BPTB grafts 3 months after surgery (Gobbi &Francisco, 2015). 
Therefore, even though hamstring grafts have many advantages compared to the BPTB grafts, they 
are far from perfect. 
Allografts 
 Autografts have been used and highly recommended for years, but their major disadvantage 
is donor site morbidity, which is where the site of the extracted graft becomes weakened, stiff, and 
sore. Allografts, on the other hand, do not have this side effect, which is why they are growing in 
popularity. Allografts involve transplanting the patellar tendons, the hamstring tendons, and 
Achilles tendons from a donor cadaver to a patient with a torn ACL (Dhammi et al. 2015). One of 
the main advantages of allografts is that there is no harvest site damage because the tendon was 
not removed from the patient. Surgery time is also shorter, and post-operative recovery is a lot 
easier (Dhammi et al. 2015). In a study by Cole et al. (2005), the authors also found that ACL 
reconstructive surgeries using allografts are much more cost efficient than surgeries involving 
BPTB autografts. They averaged about $1,000 less than the ACL reconstructive surgeries using 
patellar tendon autografts. 
 Allografts cost less money, and they offer a plethora of advantages not seen in patellar 
tendon autografts and hamstring autografts. However, there are also some major disadvantages 
when using allografts. The main limitations of allografts include disease transmission, delayed 
graft incorporation, potential immune reactions, and tunnel widening (Chang et al. 2003). Disease 
transmission is quite possibly the most dangerous disadvantage of allografts. HIV and hepatitis C 
can possibly be transmitted to a healthy patient because of an allograft, and there have also been a 
few documented cases of sepsis occurring after an allograft transplant (Chang et al. 2003). Also, 
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since the allograft was removed from a cadaver, there is a chance that the tissue may be rejected 
by the patient’s immune system (Dhammi et al. 2015). However, with new and advancing 
knowledge about certain diseases and new rejection medicines, the risk of disease transmission 
and graft rejection from an allograft is becoming less common. Still, it is a risk that makes many 
patients hesitant to get allografts over patellar tendon autografts and hamstring autografts. 
Summary 
 Patellar tendon autografts, hamstring autografts, and allografts from a donor cadaver have 
been used for a long time. They each have certain advantages and disadvantages that make them 
mostly equal when it comes to determining which graft works the best, although the patellar tendon 
autograft is still the most highly recommended (Dhammi et al. 2015). However, orthopedic doctors 
and surgeons are developing new alternatives to the traditional autografts and allografts. One of 
these alternatives involve tissue ligament engineering, which could be the future of ACL 
reconstructive surgery. 
New Tissue-Engineered Grafts 
 Tissue-engineering combines science, engineering, and medicine in order to create cells 
in vitro that can possibly grow and develop into a fully functioning tissue. Tissue-engineering 
was originally industrialized to fix skin, cartilage, and bone damage, but now doctors are 
considering it in order to produce a synthetic ACL (Rathbone et al. 2012).  In order to produce a 
functional tissue-engineered ACL, it is important to search for the right material that will mimic 
the structure of a human ACL. Collagen has been extensively studied to create a synthetic ACL 
(Vavken, Joshi, & Murray, 2009), and other prosthetic ACL’s have been developed using 
The Future of ACL Reconstructive Surgery 
9 
 
polytetrafluorethylene, polyester, and polypropylene ligament augmentation devices 
(Patinharayil, 2017). However, the results from the use of these are not very promising. 
 Even though synthetic ACLs were tested on human subjects and failed in the late 1970s 
and 1980s, they are still being studied closely as an alternative to traditional autografts and 
allografts (Patinharayil, 2017). Technology has advanced since then, so better synthetic ACLs 
are being developed. By using the appropriate cells, such as stem cells and primary fibroblasts, 
and by finding the appropriate biomimetic scaffold to design the engineered ACL, it is possible 
to make a functional tissue-engineered ACL (Yates et al. 2011). While these newly developed 
synthetics have yet to be tested on humans, a bio-enhanced scaffold treated with platelet-rich 
plasma was tested in animal ACLs, and there was significant improvement of mechanical and 
biological healing of the ruptured ACL (Nau & Teuschl, 2015). Along with some successful 
animal testing, Triton-X, a common detergent used in laboratories, was treated on ACL tissue, 
and there was efficient decellularization of the tissue without major changes to the foundation of 
the tissue. Decellularization could effectively prevent remodeling of the tissue-engineered ACL, 
and it could also prevent tunnel widening and graft rejection so that the tissue-engineered ACLs 
will be more functional in human subjects (Vavken et al.2009). Although there is more research 
and testing to be done on tissue-engineered grafts, new developments in the study of tissue-
engineering could eventually yield a tissue-engineered ACL that could potentially rival the 
traditional autografts and allografts. However, this does not necessarily mean that they will 
overall be better than traditional grafts once they are tested on humans. 
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Tissue-Engineered Grafts vs. Traditional Grafts 
Although traditional autografts and allografts have been used for years, orthopedic 
doctors are still actively searching for a better type of graft with fewer side effects for ACL 
patients. As mentioned earlier, one of the main problems with traditional autografts is that they 
can cause donor site morbidity (Rathbone et al. 2012). Allografts were an earlier alternative for 
doctors that would remove the nagging problem of donor site morbidity since the ligament is 
removed from a donor cadaver, but allografts have been known to transmit diseases from 
cadavers to healthy patients, which is why many patients are hesitant to use them (Chang et al. 
2003). In order to circumvent the problems of donor site morbidity, extended recovery periods, 
and disease transmission, doctors are now looking into tissue-engineered grafts. 
Possible Advantages of Tissue-Engineered Grafts 
 As previously stated, tissue ligament engineering is the creation of an artificial ACL 
using synthetic materials and stem cells. The reason that this would be beneficial for ACL 
reconstructive surgery is because the tissue would not be harvested from the patient, so donor 
site morbidity can be avoided. Also, the tissue will be made of the patient’s own cells, so disease 
transmission is not likely to occur (Patinharayil, 2017). Tissue-engineered grafts could 
eventually be sturdier than traditional autografts and allografts, so recovery time after ACL 
reconstructive surgery could be immensely shortened. Since tissue-engineered grafts could offer 
a solution to many problems traditional grafts cause, many orthopedic doctors are very open to 
using these grafts in the future when preforming ACL reconstructive surgery (Rathbone et al. 
2012). Tissue-engineered grafts might sound great in theory, but there has yet to be a tissue-
engineered graft made that has tested successfully on humans. 
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Disadvantages of Tissue-Engineered Grafts 
 In the 1970s and 1980s, some synthetic autografts were tested on humans. However, 
these grafts were very unsuccessful. Almost 80% of these grafts failed in a few years mainly 
because of wear and tear, tissue rejection, and mechanical problems (Patinharayil, 2017). This 
failure was disheartening to many doctors, but some used what they learned to improve the 
previously tested synthetics. Doctors looked to improve the synthetics by changing the materials 
the synthetics were made of, by testing different types of cells to make the tissue, and by trying 
to improve the mobility of these tissue-engineered ACL grafts (Yilgor et al. 2012). Even with 
these changes, many orthopedic surgeons still found problems with tissue-engineered grafts. 
These grafts are more susceptible to damage than the traditional autografts and allografts, and 
they are not very long-lasting. Some patients who received tissue-engineered grafts reported 
graft failures within the first year of using the improved grafts (Dhammi et al. 2015). Along with 
reduced durability, tissue-engineered grafts could take three to six months to be made before 
they can be harvested for surgery, while traditional autografts and allografts can be harvested 
within days to weeks of the ACL injury (Patinharayil, 2017). Therefore, even if recovery time is 
shortened because of decreased donor site morbidity, ACL patients would still have to wait an 
unusually long time just to receive the graft they need for surgery. 
Future Trends 
 Decreased durability and mobility, and the extended time it takes to form tissue-
engineered grafts are just a few of the major problems associated with artificial ACL grafts. 
However, new models of tissue-engineered grafts, that have yet to be tested on humans, are 
being created in order to combat some of these problems. As mentioned earlier, Triton-X is now 
being used to decrease the graft rejection in patients receiving a tissue-engineered graft, and it 
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can also prevent tunnel widening (Vavken et al.2009). The treatment of tissue-engineered grafts 
using Triton-X could be the key to making these grafts more durable. Along with Triton-X, 
orthopedic doctors are also working to develop a better scaffold, or a supportive structure, for the 
tissue-engineered ACLs to be designed with. One design using a “braid-twist” scaffold is being 
used to create an artificial ACL graft that is more identical to a patient’s actual ACL ligament 
(Freeman et al. 2006). This upgrade in the design of tissue-engineered grafts could improve 
mobility after the graft is implanted, make the graft more durable, and also potentially decrease 
graft rejection. 
Summary 
Unfortunately, both of these improvements, the “braid-twist” design and the addition of 
Triton-X, have not been tested on humans yet, so it is difficult to say whether this will ultimately 
make tissue-engineered grafts the new “gold-standard” when it comes to ACL reconstructive 
surgery. Therefore, since tissue-engineered grafts are still largely experimental and historically 
unsuccessful, traditional autografts and allografts should be used and relied on for the time being. 
Tissue-Engineered Autograft Implications for Athletes 
 One of the main reasons orthopedic doctors are more motivated to find an improved graft 
is because many athletes suffer from ACL injuries. In fact, individuals who participate is sports 
that involve jumping, pivoting, and cutting are at a much greater risk of rupturing their ACL than 
non-athletes (Gobbi et al. 2006). Since young athletes are usually eager to return to play, they 
must undergo ACL surgery to repair the torn ACL, which is usually a time-consuming and 
grueling task.. Many young athletes deal with nagging soreness and decreased athletic ability 
which can lead to depression because this extended recovery period causes them to miss out on 
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doing something that they love (Tripp et al. 2007). In order to combat this problem, tissue-
engineered grafts are being investigated as an alternative to decrease recovery time for athletes. 
Tendonitis and stiffness are common side effects of ACL surgeries when using traditional 
autografts and allografts, and these problems can make it difficult for athletes to return to the 
same level of play they had achieved before the ACL injury (Dhammi et al. 2015). Since these 
problems have been theorized to be eliminated with tissue engineered grafts, many athletes and 
doctors want to use these grafts for a better and faster recovery. However, even though donor site 
morbidity is eliminated, other problems such as graft failure and durability keep tissue-
engineered grafts from being a better choice for athletes. Instead of athletes, many doctors are 
now considering tissue-engineered grafts for elderly, less-active patients because tissue-
engineered grafts are easily worn-down and damaged (Patinharayil, 2017). Once the problem of 
graft durability is solved in tissue-engineered grafts, then doctors may consider transitioning 
them to athletes. Ultimately, if the major problems associated with tissue-engineered grafts are 
resolved, then these grafts may potentially become the best option for athletes. However, until 
that day comes, it is probably safest if athletes rely on traditional autografts and allografts when 
dealing with an ACL injury. 
Conclusion 
 Traditional autografts, such as the patellar tendon and hamstring grafts, and allografts are  
commonly used in the repair of a ruptured ACL. They are fairly effective, but they also have 
several side effects such as donor site morbidity, loss of muscle strength, disease transmission, 
and graft rejection. In order to avoid these problems, orthopedic doctors considered using tissue-
engineered grafts, or grafts made of synthetic material and stem cells. Tissue-engineered grafts 
would not cause problems like donor site morbidity or disease transmission, but they have other 
The Future of ACL Reconstructive Surgery 
14 
 
major flaws that keep them from currently being better than traditional autografts and allografts. 
Tissue-engineered grafts take a while to be formed, and they are also less durable. Since these 
grafts are frailer, they are more prone to failure. Presently, orthopedic doctors are working on 
ways to improve tissue-engineered grafts so that they are sturdier, but these improvements have 
yet to be tested on humans. While some doctors are optimistic, as of right now, it is impossible to 
say whether tissue-engineered grafts are better than traditional autografts and allografts. Until the 
major problems with tissue-engineered grafts are fixed and successfully tested, then ACL 
patients, especially athletes, should stick to using traditional autografts and allografts. 
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